$IMNN

Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,541 shares of Imunon, Inc. (IMNN) at $1.57 on 2026-08-03.

Original reporting
SEC EDGAR · Eylward Susan
Published Aug 4, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity but does not introduce new operational or financial information about Imunon.

02

Market read

Traders may monitor IMNN for follow-on insider activity, but this filing alone is unlikely to change valuation drivers.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon, Inc. disclosed a Form 4 showing General Counsel Eylward Susan sold 2,541 shares at $1.5651 on 2026-08-03.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment rather than fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it provides no new company performance, guidance, or deal information. The sale size is modest and the article lacks context on motivations or broader insider activity.

Market effects

No sector-level signal; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax needs and may not reflect negative expectations, especially without any accompanying negative company news.

Key entities

  • Imunon, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Eylward Susan

    General Counsel and Corp Sec who sold shares in an open-market transaction.

Related articles

$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

$IMNNMedAI 9/10

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.